The ENGAGEMENT study and virtual genetics board
“There really are many considerations regarding germline testing, results interpretation, implications for treatment or screening, and the familial hereditary implications of this whole field. Because of that, understanding the role of genetic counseling is critical, and also understanding the interplay with various somatic testing approaches is also really important,” says Veda N. Giri, MD.
In this video, members of the ENGAGEMENT study virtual genetics board discuss the importance of the program in educating patients with prostate cancer about genetic, familial and clinical complexities throughout the field. At the next case-based discussion, these experts will offer their perspectives on CT DNA testing. The genetics board includes Heather Cheng, MD, PhD, Veda N. Giri, MD, Jennifer Johnson, MD, PhD, Stacy Loeb, MD, MSc, PhD (hon), Channing Paller, MD, Jessica Russo, MS, LCGC, and Emily Weg, MD.
Study finds disparities in management of mCSPC
April 17th 2024“These findings suggest that guideline recommended treatment intensification remains low for patients with mCSPC in both Medicare and the Veterans Health Administration, but especially for Black patients,” says Daniel J. George, MD.
